The impact of pharmaceutical rebates on patients’ drug expenditures
| Autor: | Reed F. Beall, K. Ally Memedovich, Braden J. Manns, Fiona Clement, Aidan Hollis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Drug
Canada Prescription Drugs Drug Industry business.industry 030503 health policy & services media_common.quotation_subject MEDLINE Reimbursement Mechanism Accounting General Medicine Drug Costs Reimbursement Mechanisms 03 medical and health sciences 0302 clinical medicine Humans 030212 general & internal medicine Business Private insurance Cost Sharing Health Expenditures 0305 other medical science Drug industry Analysis media_common |
| Popis: | KEY POINTS Most pharmaceutical expenditure in Canada is private. In 2017, Canadian provincial, territorial and federal governments were reported to have spent $14.5 billion on pharmaceuticals, accounting for only 43% of total pharmaceutical expenditure.[1][1] A combination of private insurance and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|